Thoratec HeartMate II Continuous-Flow LVAD Poses “Acceptable” Risks
This article was originally published in The Gray Sheet
Executive Summary
A new study of Thoratec's HeartMate II continuous-flow left-ventricular assist device supports the growing consensus that patient selection has a far greater influence than device selection on the mortality rate of LVAD patients
You may also be interested in...
Advisory Panel Votes 12-0 In Favor Of Thoratec’s HeartMate II LVAD
FDA's Circulatory System Devices panel unanimously endorsed Thoratec's PMA for its HeartMate II implantable left ventricular assist device at its Nov. 30 meeting in Gaithersburg, Md
Advisory Panel Votes 12-0 In Favor Of Thoratec’s HeartMate II LVAD
FDA's Circulatory System Devices panel unanimously endorsed Thoratec's PMA for its HeartMate II implantable left ventricular assist device at its Nov. 30 meeting in Gaithersburg, Md
VAD Implant Guideline Proposal Dubbed “One Year/One Block” Strategy
Heart failure patients should be considered for ventricular assist device (VAD) implants when they can no longer walk at least one block or they have less than a year of life expectancy, according to Lynne Warner Stevenson, M.D., a cardiac surgeon at Brigham and Women's Hospital, Boston